A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

A. A. Chiappori, M. T. Schreeder, M. M. Moezi, J. J. Stephenson, J. Blakely, R. Salgia, Q. S. Chu, Helen J Ross, D. S. Subramaniam, J. Schnyder, M. S. Berger

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. Methods: Eligible patients (3-6 per cohort) had extensive-stage SCLC, measurable disease, 1 before therapy, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients were treated with escalating doses of obatoclax, either as a 3-or 24-h infusion, on days 1-3 of a 21-day cycle, in combination with carboplatin (area under the curve 5, day 1 only) and etoposide (100 mg m 2, days 1-3). The primary endpoint was to determine the maximum tolerated dose of obatoclax.Results:Twenty-five patients (56% male; median age 66 years) were enrolled in three dose cohorts for each schedule. Maximum tolerated dose was established with the 3-h infusion at 30 mg per day and was not reached with the 24-h infusion. Compared with the 24-h cohorts, the 3-h cohorts had higher incidence of central nervous system (CNS) adverse events (AEs); dose-limiting toxicities were somnolence, euphoria, and disorientation. These CNS AEs were transient, resolving shortly after the end of infusion, and without sequelae. The response rate was 81% in the 3-h and 44% in the 24-h infusion cohorts. Conclusion: Although associated with a higher incidence of transient CNS AEs than the 24-h infusion, 3-h obatoclax infusion combined with carboplatin-etoposide was generally well tolerated at doses of 30 mg per day. Though patient numbers were small, there was a suggestion of improved efficacy in the 3-h infusion group. Obatoclax 30 mg infused intravenously over 3 h on 3 consecutive days will be utilised in future SCLC studies.

Original languageEnglish (US)
Pages (from-to)839-845
Number of pages7
JournalBritish Journal of Cancer
Volume106
Issue number5
DOIs
StatePublished - Feb 28 2012

Fingerprint

Carboplatin
Small Cell Lung Carcinoma
Etoposide
Maximum Tolerated Dose
Central Nervous System
bcl-2 Genes
Confusion
Incidence
Area Under Curve
Appointments and Schedules
obatoclax
Safety
Drug Therapy

Keywords

  • apoptosis
  • Bcl-2 gene family
  • CNS symptoms
  • small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. / Chiappori, A. A.; Schreeder, M. T.; Moezi, M. M.; Stephenson, J. J.; Blakely, J.; Salgia, R.; Chu, Q. S.; Ross, Helen J; Subramaniam, D. S.; Schnyder, J.; Berger, M. S.

In: British Journal of Cancer, Vol. 106, No. 5, 28.02.2012, p. 839-845.

Research output: Contribution to journalArticle

Chiappori, A. A. ; Schreeder, M. T. ; Moezi, M. M. ; Stephenson, J. J. ; Blakely, J. ; Salgia, R. ; Chu, Q. S. ; Ross, Helen J ; Subramaniam, D. S. ; Schnyder, J. ; Berger, M. S. / A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. In: British Journal of Cancer. 2012 ; Vol. 106, No. 5. pp. 839-845.
@article{2bc4e35f80174c97a83b379189949ce1,
title = "A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer",
abstract = "Background: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. Methods: Eligible patients (3-6 per cohort) had extensive-stage SCLC, measurable disease, 1 before therapy, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients were treated with escalating doses of obatoclax, either as a 3-or 24-h infusion, on days 1-3 of a 21-day cycle, in combination with carboplatin (area under the curve 5, day 1 only) and etoposide (100 mg m 2, days 1-3). The primary endpoint was to determine the maximum tolerated dose of obatoclax.Results:Twenty-five patients (56{\%} male; median age 66 years) were enrolled in three dose cohorts for each schedule. Maximum tolerated dose was established with the 3-h infusion at 30 mg per day and was not reached with the 24-h infusion. Compared with the 24-h cohorts, the 3-h cohorts had higher incidence of central nervous system (CNS) adverse events (AEs); dose-limiting toxicities were somnolence, euphoria, and disorientation. These CNS AEs were transient, resolving shortly after the end of infusion, and without sequelae. The response rate was 81{\%} in the 3-h and 44{\%} in the 24-h infusion cohorts. Conclusion: Although associated with a higher incidence of transient CNS AEs than the 24-h infusion, 3-h obatoclax infusion combined with carboplatin-etoposide was generally well tolerated at doses of 30 mg per day. Though patient numbers were small, there was a suggestion of improved efficacy in the 3-h infusion group. Obatoclax 30 mg infused intravenously over 3 h on 3 consecutive days will be utilised in future SCLC studies.",
keywords = "apoptosis, Bcl-2 gene family, CNS symptoms, small cell lung cancer",
author = "Chiappori, {A. A.} and Schreeder, {M. T.} and Moezi, {M. M.} and Stephenson, {J. J.} and J. Blakely and R. Salgia and Chu, {Q. S.} and Ross, {Helen J} and Subramaniam, {D. S.} and J. Schnyder and Berger, {M. S.}",
year = "2012",
month = "2",
day = "28",
doi = "10.1038/bjc.2012.21",
language = "English (US)",
volume = "106",
pages = "839--845",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

AU - Chiappori, A. A.

AU - Schreeder, M. T.

AU - Moezi, M. M.

AU - Stephenson, J. J.

AU - Blakely, J.

AU - Salgia, R.

AU - Chu, Q. S.

AU - Ross, Helen J

AU - Subramaniam, D. S.

AU - Schnyder, J.

AU - Berger, M. S.

PY - 2012/2/28

Y1 - 2012/2/28

N2 - Background: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. Methods: Eligible patients (3-6 per cohort) had extensive-stage SCLC, measurable disease, 1 before therapy, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients were treated with escalating doses of obatoclax, either as a 3-or 24-h infusion, on days 1-3 of a 21-day cycle, in combination with carboplatin (area under the curve 5, day 1 only) and etoposide (100 mg m 2, days 1-3). The primary endpoint was to determine the maximum tolerated dose of obatoclax.Results:Twenty-five patients (56% male; median age 66 years) were enrolled in three dose cohorts for each schedule. Maximum tolerated dose was established with the 3-h infusion at 30 mg per day and was not reached with the 24-h infusion. Compared with the 24-h cohorts, the 3-h cohorts had higher incidence of central nervous system (CNS) adverse events (AEs); dose-limiting toxicities were somnolence, euphoria, and disorientation. These CNS AEs were transient, resolving shortly after the end of infusion, and without sequelae. The response rate was 81% in the 3-h and 44% in the 24-h infusion cohorts. Conclusion: Although associated with a higher incidence of transient CNS AEs than the 24-h infusion, 3-h obatoclax infusion combined with carboplatin-etoposide was generally well tolerated at doses of 30 mg per day. Though patient numbers were small, there was a suggestion of improved efficacy in the 3-h infusion group. Obatoclax 30 mg infused intravenously over 3 h on 3 consecutive days will be utilised in future SCLC studies.

AB - Background: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. Methods: Eligible patients (3-6 per cohort) had extensive-stage SCLC, measurable disease, 1 before therapy, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients were treated with escalating doses of obatoclax, either as a 3-or 24-h infusion, on days 1-3 of a 21-day cycle, in combination with carboplatin (area under the curve 5, day 1 only) and etoposide (100 mg m 2, days 1-3). The primary endpoint was to determine the maximum tolerated dose of obatoclax.Results:Twenty-five patients (56% male; median age 66 years) were enrolled in three dose cohorts for each schedule. Maximum tolerated dose was established with the 3-h infusion at 30 mg per day and was not reached with the 24-h infusion. Compared with the 24-h cohorts, the 3-h cohorts had higher incidence of central nervous system (CNS) adverse events (AEs); dose-limiting toxicities were somnolence, euphoria, and disorientation. These CNS AEs were transient, resolving shortly after the end of infusion, and without sequelae. The response rate was 81% in the 3-h and 44% in the 24-h infusion cohorts. Conclusion: Although associated with a higher incidence of transient CNS AEs than the 24-h infusion, 3-h obatoclax infusion combined with carboplatin-etoposide was generally well tolerated at doses of 30 mg per day. Though patient numbers were small, there was a suggestion of improved efficacy in the 3-h infusion group. Obatoclax 30 mg infused intravenously over 3 h on 3 consecutive days will be utilised in future SCLC studies.

KW - apoptosis

KW - Bcl-2 gene family

KW - CNS symptoms

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84857794915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857794915&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.21

DO - 10.1038/bjc.2012.21

M3 - Article

C2 - 22333598

AN - SCOPUS:84857794915

VL - 106

SP - 839

EP - 845

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -